Advertisement
U.S. markets closed
Advertisement

Gamida Cell Ltd. (GMDA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.3200-0.0060 (-1.84%)
At close: 04:00PM EST
0.3300 +0.01 (+3.13%)
After hours: 07:48PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close0.3260
Open0.3338
Bid0.3233 x 900
Ask0.3300 x 1000
Day's Range0.3150 - 0.3338
52 Week Range0.2200 - 2.5100
Volume1,342,587
Avg. Volume1,879,963
Market Cap42.444M
Beta (5Y Monthly)1.25
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GMDA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Gamida Cell Ltd.
    Analyst Report: AbbVie Inc.AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • GlobeNewswire

    Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023

    BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, is hosting a virtual fireside chat with thought leader Gary Schiller, MD, FACP, Professor of Medicine and Director of the Hematological Malignancy & Stem Cell Transplant Program at the David Geffen School of Medicine at University of California – Los Angeles. Dr. Schiller will discuss his experience working with patients in need of allogeneic stem ce

  • GlobeNewswire

    Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference

    BOSTON, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that its management team will present corporate highlights at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY. Presentation Details Format:Fireside ChatDate/Time:Tuesday, November 28, 2023 at 11:00 –11:25 AM ETWebcast:Click here. The Gamida Cell management team will be available for one-on-one meetings dur

  • GlobeNewswire

    Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update

    Company continues to advance launch, reports initial revenue from Omisirge® (omidubicel-onlv) Company to host conference call today at 8:30 a.m. ET BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today reported financial results for the quarter ended September 30, 2023, and provided a business update. “The third quarter marked the first patients receiving Omisirge following FDA approval and the po